1Año·

Teladoc Q2’25 Earnings Highlights

$TDOC (-5,02 %)


🔹 Revenue: $631.9M (Est. $622.5M) 🟢; -2% YoY

🔹 EPS: ($0.19) (Est. ($0.26)) 🟢


FY25 Guidance:

🔹 Revenue: $2.50B–$2.55B (Est. $2.2B) 🟢

🔹 EPS: ($1.35)–($1.00) (Est. ($1.16)) 🟡

🔹 Adjusted EBITDA: $263M–$294M

🔹 Free Cash Flow: $170M–$200M

🔹 Integrated Care Rev Growth: +1.75%–3.25%; EBITDA Margin: 14.5%–15.25%

🔹 BetterHelp Rev Growth: -9.2% to -6.8%; EBITDA Margin: 4%–5.5%


Q3 Guide:

🔹 Revenue: $614M–$636M (Est. $627.9M) 🟡

🔹 EPS: ($0.35)–($0.20) (Est. ($0.24)) 🟡

🔹 Adjusted EBITDA: $56M–$70M

🔹 Integrated Care Rev Growth: -0.5% to +2.25%; EBITDA Margin: 14%–15.5%

🔹 BetterHelp Rev Growth: -9.75% to -5%; EBITDA Margin: 1%–3.75%


Other Q2 Metrics:

🔹 Adj EBITDA: $69.3M; DOWN -23% YoY

🔹 Free Cash Flow: $61.2M vs. $60.9M YoY

🔹 Integrated Care Rev: $391.5M; UP +4% YoY

🔹 BetterHelp Rev: $240.4M; DOWN -9% YoY

🔹 Integrated Care EBITDA Margin: 14.7%

🔹 BetterHelp EBITDA Margin: 4.9%


CEO Commentary

🔸 “Revenue and EBITDA came in at the high end of our guidance range.”

🔸 “We’re executing with discipline and investing in product innovation.”

🔸 “Virtual care can be a performance multiplier in an evolving healthcare landscape.”

2
Únase a la conversación